John E. Norris
YOU?
Author Swipe
View article: Magnesium isotope ratios in Milky Way and dwarf galaxy stars
Magnesium isotope ratios in Milky Way and dwarf galaxy stars Open
Under the assumption of hierarchical galaxy formation, dwarf galaxies are the closest existing analogues to the high-redshift protogalaxies that merged to form the Milky Way. These low-mass systems serve as unique laboratories for studying…
View article: Utilization of Depression Screening in Patients with Type 2 Diabetes Mellitus
Utilization of Depression Screening in Patients with Type 2 Diabetes Mellitus Open
The purpose of this DNP project is to determine the effectiveness of screening patients with Type 2 Diabetes Mellitus for depression using the PHQ-9 screening tool. Specific Aims• Aims to investigate the feasibility and effectiveness of im…
View article: Bright metal-poor stars from the Hamburg/ESO survey I: selection and follow-up observations from 329 fields
Bright metal-poor stars from the Hamburg/ESO survey I: selection and follow-up observations from 329 fields Open
We present a sample of 1777 bright (9 < B < 14) metal-poor candidates selected from the Hamburg/ESO Survey (HES). Despite saturation effects present in the red portion of the HES objective-prism spectra, the data were recoverable and quant…
View article: Metal-poor stars observed with the <i>Magellan Telescope</i> – IV. Neutron-capture element signatures in 27 main-sequence stars
Metal-poor stars observed with the <i>Magellan Telescope</i> – IV. Neutron-capture element signatures in 27 main-sequence stars Open
We present a chemo-dynamical analysis for 27 near main-sequence turnoff metal-poor stars, including 20 stars analysed for the first time. The sample spans a range in [Fe/H] from −2.5 to −3.6, with 44 per cent having [Fe/H]<−2.9. We deri…
View article: Metal-poor stars observed with the Magellan Telescope. IV. Neutron-capture element signatures in 27 main-sequence stars
Metal-poor stars observed with the Magellan Telescope. IV. Neutron-capture element signatures in 27 main-sequence stars Open
Based on high-resolution spectra obtained with Magellan/MIKE, we present a chemo-dynamical analysis for 27 near main-sequence turnoff metal-poor stars, including 20 stars analyzed for the first time. The sample spans a range in [Fe/H] from…
View article: Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
ESR1 mutants are resistant to endocrine therapies in vitro and in vivo and H3B-5942 can suppress ER pathway activity.
View article: Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Additional methods provided.
View article: Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-r…
View article: Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-r…
View article: Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 suppresses co-activator recruitment and shows potency in endocrine sensitive and resistant lines
View article: Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 suppresses co-activator recruitment and shows potency in endocrine sensitive and resistant lines
View article: Figures S20-S23 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S20-S23 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 in combination with palbocyclib shows synergy in vitro and in vivo
View article: Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Additional methods provided.
View article: Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Crystallography and amino acid coordinates
View article: Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Crystallography and amino acid coordinates
View article: Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
C530 residue is critical for H3B-5942 potency
View article: Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Enriched GSEA pathways
View article: Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 exhibits dose-dependent inhibition of ER target genes and shows significant efficacy ER Wt and mutant in vivo models
View article: Figures S20-S23 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S20-S23 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 in combination with palbocyclib shows synergy in vitro and in vivo
View article: Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
Enriched GSEA pathways
View article: Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
H3B-5942 exhibits dose-dependent inhibition of ER target genes and shows significant efficacy ER Wt and mutant in vivo models
View article: Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
C530 residue is critical for H3B-5942 potency
View article: Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer Open
ESR1 mutants are resistant to endocrine therapies in vitro and in vivo and H3B-5942 can suppress ER pathway activity.
View article: A critique of the Spite Plateau and the astration of primordial lithium
A critique of the Spite Plateau and the astration of primordial lithium Open
We investigate the distribution of the lithium abundances, A(Li), of metal-poor dwarf and subgiant stars within the limits 5500 K < Teff < 6700 K, −6.0 < [Fe/H] < −1.5, and log g ≳ 3.5 (a superset of parameters first adopted by…
View article: Detailed Chemical Abundances of Stars in the Outskirts of the Tucana II Ultrafaint Dwarf Galaxy*
Detailed Chemical Abundances of Stars in the Outskirts of the Tucana II Ultrafaint Dwarf Galaxy* Open
We present chemical abundances and velocities of five stars between 0.3 and 1.1 kpc from the center of the Tucana II ultrafaint dwarf galaxy (UFD) from high-resolution Magellan/MIKE spectroscopy. We find that every star is deficient in met…
View article: Evidence of globular cluster abundance anomalies in the SMC intermediate-age cluster Kron 3
Evidence of globular cluster abundance anomalies in the SMC intermediate-age cluster Kron 3 Open
Using spectra obtained with the VLT/FORS2 and Gemini-S/GMOS-S instruments, we have investigated carbon, nitrogen, and sodium abundances in a sample of red giant members of the Small Magellanic Cloud star cluster Kron 3. The metallicity and…
View article: Detailed chemical abundances of stars in the outskirts of the Tucana II ultra-faint dwarf galaxy
Detailed chemical abundances of stars in the outskirts of the Tucana II ultra-faint dwarf galaxy Open
We present chemical abundances and velocities of five stars between 0.3 kpc to 1.1 kpc from the center of the Tucana II ultra-faint dwarf galaxy (UFD) from high-resolution Magellan/MIKE spectroscopy. We find that every star is deficient in…
View article: High-resolution spectroscopic follow-up of the most metal-poor candidates from SkyMapper DR1.1
High-resolution spectroscopic follow-up of the most metal-poor candidates from SkyMapper DR1.1 Open
We present chemical abundances for 21 elements (from Li to Eu) in 150 metal-poor Galactic stars spanning −4.1 < [Fe/H] < −2.1. The targets were selected from the SkyMapper survey and include 90 objects with [Fe/H] ≤ −3 of which some …